These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-004557-25 Phase II study of Brostallicin a(PNU- 166196) and Cisplatin (CDDP) in Adult Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)preceded by a dose-escalation component bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000731-26 Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by dose... 2012-04-19 bad-data
Completed, but no date 2005-004200-36 Phase II exploratory study of brostallicin PNU-166196A as third/fourth line chemoterapy in adult patients with advanced/metastatic colorectal cancer CRC . bad-data
Completed, but no date 2005-005646-39 Phase II exploratory study of brostallicin PNU-166196A in patients with ovarian cancer resistant/refractory to platinum based chemotherapy. bad-data
Not reported 2006-000798-31 Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma 2007-05-16 due-trials
Listed as ongoing, but also has a completion date 2006-001861-40 Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma 2009-12-08 bad-data
Ongoing, reported early 2006-003193-10 A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-003772-35 Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers. 2012-08-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-006136-21 A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. 2011-03-23 bad-data
Completed, but no date, and reported results 2006-006881-40 A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy bad-data
Ongoing, reported early 2007-005425-30 An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression not-yet-due
Completed, but no date, and reported results 2008-005831-13 Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients bad-data
Ongoing 2009-014338-79 Phase II study of oral PHA-848125AC in patients with thymic carcinoma previously treated with chemotherapy not-yet-due
Ongoing 2013-000344-25 Phase II study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy not-yet-due